What is the expected growth forecast for the PGD market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the PGD market?

Advances in genetic testing and increasing awareness of genetic disorders drive the market.

What challenges does the PGD market face?

High costs and limited insurance coverage are significant challenges for the PGD market.

Which regions are the leaders in the PGD market?

North America and Europe are the leading regions in the PGD market.

Who are the top companies in the PGD market?

Illumina, Thermo Fisher, and Agilent are among the top companies in the PGD market.

What future opportunities exist in the PGD market?

Emerging markets and advances in technology offer significant future opportunities.

How does technology impact the PGD market?

Next-generation sequencing and AI advancements improve the accuracy and efficiency of PGD.

What is the current regulatory landscape for the PGD market?

The regulatory landscape varies by region, with strict guidelines in Europe and the US.

What is the future outlook for the PGD market?

The future outlook is positive, with increasing demand for genetic testing and diagnosis.

Pre-Implantation Genetic Diagnosis (PGD) Growth Trends & Opportunity Analysis 2033

Pre-Implantation Genetic Diagnosis (PGD) by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $106.6 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Jan 10, 2026Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $106.6 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Jan 10, 2026Updated: Jun 8, 2026

Loading report content...

Loading report...

Pre-Implantation Genetic Diagnosis (PGD) Market Size | CAGR 4.3% Forecast 2033

Pre-Implantation Genetic Diagnosis (PGD) Growth Trends & Opportunity Analysis 2033

Pre-Implantation Genetic Diagnosis (PGD) by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $106.6 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Jan 10, 2026Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $106.6 million

CAGR: 4.3%

Historical Range: 2020 - 2025

Jan 10, 2026Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pre-Implantation Genetic Diagnosis (PGD) Market Overview

The Pre-Implantation Genetic Diagnosis (PGD) market refers to the industry involved in the genetic testing of embryos prior to implantation during in vitro fertilization (IVF) procedures. As a crucial aspect of reproductive genetics, the Pre-Implantation Genetic Diagnosis (PGD) market size is witnessing significant growth, driven by advancements in genetic testing technologies and increasing awareness about genetic disorders. The growth outlook for the PGD market is promising, with a market forecast indicating a compound annual growth rate (CAGR) of approximately 10% during the forecast period. Key drivers of this industry expansion include the rising incidence of genetic disorders, growing demand for IVF procedures, and ongoing technology shifts that enhance the accuracy and efficiency of genetic testing. The current Pre-Implantation Genetic Diagnosis (PGD) market size is estimated to be around $4.5 billion.

Loading chart…

The PGD market is influenced by several key forces, including regulatory frameworks, consumer behavior, and competitive intensity. The largest region for the PGD market is currently North America, driven by the high adoption of advanced genetic testing technologies and a large patient population. The fastest-growing region is expected to be the Asia-Pacific, fueled by increasing awareness about genetic disorders and growing investments in healthcare infrastructure. As the PGD market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, drivers, and challenges shaping the industry.

Report Overview

Report Attribute	Details
Market size value in 2025	106.60 million
Revenue forecast in 2033	185.92 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Light source type, interior design, application, end use, region
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acuity Inc.; Cree Lighting USA LLC.; Samsung Electronics; Signify Holding; OSRAM GmbH; Savant Systems, Inc.; Vakkerlight; Digital Lumens; Jainsons Emporio; Hudson Valley Lighting Group; Tom Dixon; Flos; Louis Poulsen; Bover, S.L.; Vibia
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Pre-Implantation Genetic Diagnosis (PGD) market is witnessing significant growth, driven by increasing awareness about genetic disorders and the importance of early diagnosis. The Pre-Implantation Genetic Diagnosis (PGD) market size is expected to expand substantially over the forecast period, driven by advances in genetic testing technologies and growing demand for personalized medicine.

Growth Drivers2 items

Advances in genetic testing technologies, such as next-generation sequencing, are driving the adoption of Pre-Implantation Genetic Diagnosis (PGD), enabling accurate and efficient diagnosis of genetic disorders.

Increasing awareness about genetic disorders and the importance of early diagnosis are fueling the demand for PGD, particularly among couples with a history of genetic disorders or infertility.

Restraints2 items

High costs associated with Pre-Implantation Genetic Diagnosis (PGD) procedures are limiting accessibility, particularly in developing regions with limited healthcare infrastructure and funding.

Stringent regulatory frameworks governing the use of genetic testing technologies are hindering the growth of the PGD market, as companies must navigate complex approval processes and comply with evolving regulations.

Opportunities2 items

The growing demand for Pre-Implantation Genetic Diagnosis (PGD) in emerging markets presents opportunities for companies to expand their presence and develop targeted solutions for these regions.

The integration of artificial intelligence and machine learning technologies in PGD is expected to enhance diagnostic accuracy and efficiency, creating new opportunities for innovation and growth.

Challenges2 items

The Pre-Implantation Genetic Diagnosis (PGD) market faces challenges related to data privacy and security, as sensitive genetic information must be protected and maintained in compliance with regulations.

The growth forecast for the PGD market may be impacted by reimbursement challenges, as payers and policymakers debate the coverage and funding of genetic testing procedures.

Market Segmentation

Loading chart…

The Pre-Implantation Genetic Diagnosis (PGD) segmentation by application is a crucial aspect of understanding the market taxonomy. This segmentation category contributes to the overall PGD market size by highlighting the various uses of PGD in different medical fields. The application segment can be further divided into subtypes, including aneuploidy, genetic disorders, and HLA typing. Each subtype has its own unique characteristics and requirements, driving the demand for PGD services.

The aneuploidy segment is a significant contributor to the PGD market, as it involves the diagnosis of chromosomal abnormalities in embryos. This subtype is critical in reducing the risk of miscarriages and failed pregnancies. The genetic disorders segment, on the other hand, focuses on identifying inherited disorders in embryos, allowing for informed decision-making by prospective parents. The HLA typing segment is used to match embryos with siblings or other family members who require a transplant, making it a vital application of PGD.

Regional Insights

Loading chart…

The Pre-Implantation Genetic Diagnosis (PGD) market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of PGD services, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, high ecosystem maturity, increasing demographics of individuals seeking fertility treatments, and favorable policies; for Europe, high adoption rates, advanced infrastructure, and significant investments in research and development; for Asia Pacific, growing demand for PGD services, improving infrastructure, and increasing awareness about genetic disorders; for Latin America, rising demand for fertility treatments, increasing investments in healthcare, and growing awareness about PGD; and for Middle East & Africa, increasing adoption of PGD services, improving infrastructure, and favorable policies.

The regional forecast indicates that the PGD market will experience significant growth in the coming years, driven by increasing demand for genetic testing and counseling services. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Pre-Implantation Genetic Diagnosis (PGD) market is moderately consolidated, driven by a mix of global players and local/regional companies. The PGD competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and regulatory approvals to maintain their market position, while local players are competing on pricing and distribution.

Companies in the PGD market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are employing distinct strategies:

Illumina focuses on innovation pipeline

Thermo Fisher pursues regional expansion

Agilent targets premium pricing

PerkinElmer emphasizes vertical integration

Abbott prioritizes OEM tie-ups

Roche concentrates on local manufacturing

Market Ecosystem

The Pre-Implantation Genetic Diagnosis (PGD) ecosystem encompasses a complex network of stakeholders, spanning from technology providers and suppliers to channels and end users. This ecosystem can be broadly categorized into upstream, midstream, and downstream segments, with value created and captured at each stage. The upstream segment comprises raw material and component suppliers, while the midstream segment involves technology providers, system integrators, and manufacturers. The downstream segment includes distributors, service providers, and end users, highlighting the multifaceted nature of the PGD ecosystem.

Raw material/component suppliers — provide genetic testing materials

Technology providers — develop genetic diagnosis platforms

System integrators / EPCs — integrate PGD systems

Distributors / channel partners — distribute PGD products

Service providers / after-sales — offer maintenance and support

End users / buyers — fertility clinics and patients

Regulators/standards bodies — establish guidelines and standards

The flow of value within the PGD ecosystem is influenced by various control points, including regulatory bodies that oversee standards and approvals. Dependency risks, such as input constraints and approval timelines, can impact the ecosystem's efficiency. Switching costs and partnerships also play a crucial role, as companies may need to adapt to new technologies or form alliances to remain competitive. Furthermore, the PGD ecosystem may differ by region due to varying regulatory environments and market demands, underscoring the need for a thorough value chain analysis to navigate these complexities.

Recent Industry Insights

The Pre-Implantation Genetic Diagnosis (PGD) industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships, such as the collaboration between Illumina and Reproductive Genetics Institute, have expanded the reach of PGD services. Recent mergers and acquisitions, including the acquisition of Good Start Genetics by Invitae, have also contributed to the growth of the industry.

Furthermore, there have been several product launches and technological advancements, such as the introduction of next-generation sequencing (NGS) for PGD. Regulatory changes, like the update to the European Society of Human Genetics' guidelines, have also impacted the industry. Additionally, funding rounds, including the investment in PGD companies like Genomics PLC, have supported the expansion of PGD services, driving the Pre-Implantation Genetic Diagnosis (PGD) industry trends forward.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Pre-Implantation Genetic Diagnosis (PGD) market outlook. The market exhibits a moderate level of attractiveness, driven by increasing demand for genetic testing and advancements in reproductive technology. The competitive intensity is relatively high, with key players investing heavily in research and development to improve PGD techniques and expand their market share.

The long-term outlook for the PGD market is promising, with innovations in genetic sequencing and next-generation sequencing technologies expected to drive growth. However, the demand-supply balance is a key concern, with a shortage of skilled professionals and high equipment costs limiting the availability of PGD services. Key risk factors include regulatory challenges and ethical concerns surrounding the use of PGD. Overall, the PGD market is poised for significant growth, driven by increasing awareness and adoption of genetic testing.

11 items

1. Executive Summary

2. Pre-Implantation Genetic Diagnosis (PGD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pre-Implantation Genetic Diagnosis (PGD) Market Outlook & Forecast (2021-2033) Value (USD Million)

7. Global Pre-Implantation Genetic Diagnosis (PGD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pre-Implantation Genetic Diagnosis (PGD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

8. Global Pre-Implantation Genetic Diagnosis (PGD) Market Competition by Key Manufacturers

8.1. Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pre-Implantation Genetic Diagnosis (PGD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

16 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pre-Implantation Genetic Diagnosis (PGD) Market

Figure 4: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Drivers

Figure 5: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Challenges

Figure 6: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Trends

Figure 7: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Opportunity

Figure 8: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Restraint

Figure 9: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Porter's Five Forces

Figure 10: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 11: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2024)

Figure 12: Top 5 Manufacturers

Figure 13: Top 3 Manufacturers

Figure 14: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Figure 15: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By: Regions (2032)

Figure 16: Data Triangulation

List of Tables

23 items

Table 1: Market Segmentation Analysis

Table 2: Global Pre-Implantation Genetic Diagnosis (PGD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 3: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 4: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By Region

Table 5: North America Market Value (USD Million) (2020-2024) By Country

Table 6: Europe Market Value (USD Million) (2020-2024) By Country

Table 7: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 8: South America Market Value (USD Million) (2020-2024) By Country

Table 9: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 10: Global Pre-Implantation Genetic Diagnosis (PGD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 11: Global Pre-Implantation Genetic Diagnosis (PGD) Market: Profiled Players Head Office And Area Served

Table 12: Key Players Global Pre-Implantation Genetic Diagnosis (PGD) Market:

Table 13: Mergers & Acquisitions, Expansion Plans

Table 14: Global Pre-Implantation Genetic Diagnosis (PGD) Market Value (USD Million) By Region

Table 15: Global Pre-Implantation Genetic Diagnosis (PGD) Market Share (%) By Region (2025-2032)

Table 16: North America Market Value (USD Million) (2025-2032) By Country

Table 17: Europe Market Value (USD Million) (2025-2032) By Country

Table 18: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 19: South America Market Value (USD Million) (2025-2032) By Country

Table 20: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 21: Research Programs/Design For This Report

Table 22: Key Data Information From Secondary Sources

Table 23: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…